RecruitingNot ApplicableNCT05719415

Functional Pulmonary Capillary Surface Area in BPA for CTEPH

Assessment of Recovery of Functional Capillary Surface Area in Patients Undergoing a Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension


Sponsor

Jewish General Hospital

Enrollment

40 participants

Start Date

Mar 23, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Chronic thromboembolic pulmonary hypertension \[CTEPH\] is caused by pulmonary emboli that have enlarged in pulmonary arteries and have become organized into the vessel wall. Many patients with CTEPH are treated with balloon pulmonary angioplasty \[BPA\] which mechanically opens the narrow pulmonary arteries. It is unclear how much downstream functional pulmonary capillary surface area \[FCSA\] is recovered during BPA. The investigators plan to measure FCSAIn CTEPH patients, before and after a session of BPA.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria1

  • All patients eligible for balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension

Exclusion Criteria2

  • Treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers,
  • Presence of patent foramen ovale

Interventions

OTHERMeasurement of pulmonary functional capillary surface area

Measurement of transpulmonary metabolism of trace injected doses of benzoyl-Phe-Ala-Pro


Locations(1)

David Langleben

Montreal, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05719415


Related Trials